Approval · Notice of Compliance 30965 · 2023
MENACTRA: Notice of Compliance 30965
Issued June 6, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 30965
- Date
- June 6, 2023
- Company
- Sanofi Pasteur LimitedSwiftwater, Pennsylvania, United States
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Labelling updates
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| MENACTRA | Not yet assigned | — |
Medicinal ingredients
- MENINGOCOCCAL POLYSACCHARIDE-DIPHTHERIA TOXOID CONJUGATE, GROUP A 4 MCG per 0.5ML
- MENINGOCOCCAL POLYSACCHARIDE-DIPHTHERIA TOXOID CONJUGATE, GROUP C 4 MCG per 0.5ML
- MENINGOCOCCAL POLYSACCHARIDE-DIPHTHERIA TOXOID CONJUGATE, GROUP Y 4 MCG per 0.5ML
- MENINGOCOCCAL POLYSACCHARIDE-DIPHTHERIA TOXOID CONJUGATE, GROUP W 135 4 MCG per 0.5ML